Melanotan-II Research Guide: Structure, Receptor Pharmacology, Preclinical Findings and Handling

For laboratory research use only; not for human consumption. This guide brings together the structure, history, receptor pharmacology and handling of melanotan-II as a research reagent, so that investigators can design receptor-assay and cell-model experiments with a clear view of what the molecule is, what it can and cannot show, and how to document it.

What melanotan-II is

Melanotan-II, also written MT-2 or MT-II, is a laboratory-designed analog of α-MSH, the 13-residue melanocortin peptide cleaved from pro-opiomelanocortin. The natural hormone is linear and is broken down quickly by peptidases, which limits its usefulness as a reagent. MT-2 keeps the central message sequence that melanocortin receptors recognize (His-Phe-Arg-Trp), discards the parts of the parent chain that are not needed for receptor engagement, and constrains the remainder into a ring. The result is a short, rigid, protease-resistant ligand that engages several receptor subtypes with high potency.

In the research literature MT-2 plays the role of a broad probe. Because it activates multiple melanocortin receptors rather than one, it is useful for asking whether a given tissue or cell responds to melanocortin signaling at all, and it is then paired with selective tools to work out which receptor is responsible. It is also the reference point against which more subtype-focused molecules, such as PT-141, are compared. A catalog-level summary is in the melanotan-II research overview.

Discovery and history

The melanocortin field grew out of classical bioassays: α-MSH was recognized by its ability to disperse pigment granules in amphibian skin, and analogs were ranked by how much and for how long they darkened skin preparations. In 1980, Sawyer and colleagues reported 4-norleucine,7-D-phenylalanine-α-MSH, a linear analog with markedly increased potency and what they described as ultralong biological activity. The two substitutions are instructive: norleucine replaces the oxidation-prone methionine, and D-phenylalanine in the core resists proteolysis and favors a receptor-friendly turn. That linear molecule is a direct ancestor of MT-2.

The next step was conformational constraint. Work from the Hruby laboratory at the University of Arizona, including a 1989 report by Al-Obeidi and colleagues, designed cyclic lactam analogs of α-MSH using modeling to guide ring closure, producing a class of superpotent cyclic melanotropins. Melanotan-II is the best-known member. Cyclization removes the free ends that exopeptidases attack and rigidifies the backbone, extending functional lifetime in assay media. The same scaffold later informed the development of the more MC4R-focused PT-141, which differs from MT-2 by its C-terminal group.

Older reports describe biological outcomes before receptor subtypes were cloned and characterized. With cloned receptors, selective antagonists and knockout animals, those observations can be revisited and attributed more precisely, so MT-2's history reflects a shift from broad physiological description to subtype-aware pharmacology. The practical consequence is that the compound is best framed today as a receptor probe whose breadth reveals system responsiveness but requires subtype-specific controls for mechanistic attribution. The narrative version is in melanotan-II discovery and history.

Chemical structure and synthesis

Reading the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ from left to right: Ac is an acetylated N-terminus; Nle is norleucine, a straight-chain isomer of leucine standing in for methionine; the brackets enclose the six residues in the ring; and NH₂ is the amidated C-terminus. The ring is formed by an amide (lactam) bond between the side-chain carboxyl of aspartic acid and the side-chain amine of lysine. Inside it sits the His-D-Phe-Arg-Trp core, held in a turn that favors receptor binding. Principles for reading modified sequences like this one are covered in understanding amino acid sequences.

MT-2 is built by solid-phase peptide synthesis. The linear precursor is assembled on a resin, the lactam bridge is formed on or off the resin using orthogonally protected Asp and Lys side chains, and the peptide is then cleaved, purified by chromatography and lyophilized (what is lyophilization). Successful assembly of the linear precursor does not itself prove the ring formed. Cyclization conditions must favor the intramolecular bond over intermolecular products or unreacted material, and the product must be checked: the cyclic peptide has a mass about 18 Da (one water) lower than the open-chain form, which is why mass spectrometry is a central identity test. Chromatography removes related species, while mass analysis confirms composition; HPLC versus mass spectrometry explains how the two complement each other. More detail is in melanotan-II structure and synthesis.

Mechanism of action

Melanocortin receptors are G-protein-coupled receptors. Activation of MC1R, MC3R, MC4R and MC5R by an agonist is associated in model systems with stimulation of adenylyl cyclase and a rise in intracellular cyclic AMP, which is why cAMP accumulation in receptor-expressing cells is the standard readout of potency and efficacy. MT-2 is a full, high-potency agonist across these subtypes. MC2R is the exception: it responds selectively to ACTH and is not meaningfully engaged by MT-2.

Receptor-by-receptor readouts

Each subtype is tied to different laboratory endpoints, which is what makes a broad agonist useful as a mapping tool:

• MC1R: expressed on melanocytes; activation raises cAMP and shifts pigment synthesis toward eumelanin, measured as tyrosinase activity and melanin content in melanocyte or melanoma cultures.
• MC3R: linked in rodent work to energy partitioning and related central readouts.
• MC4R: expressed in hypothalamic and brainstem circuits; linked in rodent studies to feeding behavior and energy expenditure.
• MC5R: associated with exocrine-gland function in model systems.

Dissecting subtype contributions

Because MT-2 is broad, an observed response cannot be assigned automatically to one receptor. Attribution requires additional tools: subtype-selective or mixed antagonists such as SHU9119 (an MC3R/MC4R antagonist), the endogenous antagonists agouti and agouti-related protein, engineered cell lines expressing a single subtype, and receptor-knockout animals. An effect that disappears when one receptor is blocked or absent can be assigned to it; mice lacking MC4R, for example, do not show the feeding response to MT-2, which is strong evidence for that assignment. Comparing potency across matched assay systems is more informative than comparing values generated by different laboratories with different receptor expression levels.

Time course and controls

Negative controls should confirm that the signal depends on receptor expression and not on nonspecific assay effects. Time courses and concentration-response curves help separate an early cAMP event from later transcriptional or pigment-related changes. Receptor-level observations in models describe the behavior of the tested system and should be reported as such; they are not outcomes outside the model. The mechanistic walk-through is expanded in melanotan-II mechanism of action.

Preclinical research findings

Preclinical work with MT-2 covers receptor pharmacology in cells, classical skin bioassays and rodent studies of melanocortin-dependent behavior. The table lists the main system types and what each is used to measure.

A well-known illustration comes from Fan and colleagues (Nature, 1997), who used MT-2 together with the antagonist SHU9119 to show that central melanocortin receptors regulate feeding in rodents and that the agouti obesity syndrome reflects antagonism of that pathway. It remains a standard example of using an agonist/antagonist pair to assign a function to a receptor.

A second theme is prolonged activity. The 1980 characterization by Sawyer and colleagues showed that analogs in this family act far longer than the native hormone in bioassays. Cyclization and the D-amino acid both reduce protease susceptibility, and slow dissociation from the receptor has also been proposed. For experimental design this means that time-course measurements are more informative than single time points and that washout periods must be long enough to return a system to baseline. Species matter as well: receptor distribution and pharmacology differ between rodents and other mammals, and in animal work central versus peripheral exposure can produce different profiles because access of the peptide to brain receptors is limited. Vehicle composition, time of day and feeding state also influence melanocortin-dependent behaviors, so careful studies report them alongside the results. Concentration ranges should be justified against the measured potency at each receptor. Additional notes are in melanotan-II preclinical research, and common methodological questions are answered in the melanotan-II research FAQ.

Handling, reconstitution and storage

MT-2 is supplied as a lyophilized powder. Keep it sealed, cold and dark until needed; the tryptophan residue is sensitive to light and oxidation, so amber vials or foil wrapping and minimal bench exposure are sensible. Allow the vial to reach room temperature before opening to avoid condensation. For solution work, bacteriostatic water suits a multi-use refrigerated stock, whereas sterile water is better for stocks that will be aliquoted immediately or added to cell culture, where benzyl alcohol should be accounted for with a vehicle control. Add the diluent slowly down the inside wall of the vial, swirl gently and avoid vortexing. The general method is in the lyophilized peptide reconstitution guide; compound-specific notes are in melanotan-II reconstitution and storage, and general cold-chain practice is in storing research peptides.

Stock concentration is a matter of arithmetic: mg of peptide divided by mL of diluent added. The reconstitution calculator does this for any vial, and the table below converts common stocks to molar units using 1,024.2 g/mol. For exact molar work, correct for the net peptide content and purity on the certificate of analysis.

Reconstituted solutions are usually divided into single-use aliquots so that no tube is thawed twice, and a conservative window of about 28 days at 2-8 °C is the convention for a preserved multi-use vial. These are laboratory conventions rather than validated shelf lives for a particular lot. Label each tube with compound, lot, concentration and date.

Purity, COA and quality

With a cyclic, modified peptide, the certificate of analysis carries more weight than usual, because the key structural claim (that the ring has actually closed) is a mass question as much as a purity question. A useful review routine is to check that the vial's lot number appears on the certificate, to look at the chromatogram itself and not only the summary percentage, to confirm the measured mass is close to 1,024 Da, and to log batch, storage history and preparation date in the experimental record. That routine turns the reagent into a documented variable, which is what reviewers and collaborators need to reproduce a finding.

Certificates are collected on the COA page. Analytical specifics, including how melanotan-II is told apart from related analogs, are in melanotan-II purity testing, with general background in how to read a COA and understanding HPLC purity. For the product listing see MT-2, and for sourcing criteria see where to buy melanotan-II.

Related compounds and comparisons

MT-2 sits at the broad end of the melanocortin ligand spectrum. PT-141 (bremelanotide) shares its scaffold but is studied for a more MC4R-focused profile, and the two differ structurally by one C-terminal group, as laid out in PT-141 structure and synthesis. At the other extreme, KPV keeps only the C-terminal tail of α-MSH and lacks the receptor-recognition core, so it is used to probe non-receptor-driven behavior; the contrast is developed in KPV vs α-MSH.

Frequently asked questions

What receptors does melanotan-II activate?

In cell-based assays it is an agonist at MC1R, MC3R, MC4R and MC5R. MC2R, the ACTH receptor, is not meaningfully engaged. Potency at each subtype is usually measured as cAMP accumulation in cells expressing a single receptor.

What is the sequence of melanotan-II?

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The acetylated N-terminus, norleucine, D-phenylalanine, lactam ring and amidated C-terminus are all deliberate modifications of the native α-MSH sequence.

Why is melanotan-II cyclic instead of linear?

The lactam ring between aspartic acid and lysine holds the His-D-Phe-Arg-Trp core in a receptor-favorable turn and removes free ends that peptidases attack, so the peptide persists longer in assay media than linear α-MSH.

Why is norleucine used in place of methionine?

Methionine's sulfur oxidizes easily, changing a peptide's properties during storage and assays. Norleucine has a similar shape without sulfur, making the analog chemically more robust.

What molecular mass should a certificate of analysis show?

About 1,024 Da for the cyclized, acetylated, amidated heptapeptide. A mass about 18 Da higher indicates open-chain peptide in which the ring has not formed.

How do researchers tell which receptor produced a response?

By combining the agonist with subtype-selective or mixed antagonists such as SHU9119, using single-receptor cell lines, or using knockout animals. An effect lost when one receptor is blocked or absent can be assigned to that receptor.

How does melanotan-II differ from PT-141?

They share a scaffold, but PT-141 has a free C-terminal carboxylic acid where melanotan-II has an amide, a difference of about 1 Da, and is studied for a more MC4R-focused profile. Telling them apart analytically requires care.

How do I prepare a stock solution for assays?

Divide the peptide mass in the vial by the diluent volume: 10 mg in 2 mL gives 5 mg/mL, about 4.9 mM at 1,024.2 g/mol. The calculator on this site handles other volumes.

How should lyophilized and reconstituted material be stored?

Keep the powder cold, dry and protected from light, since tryptophan is light- and oxidation-sensitive. Reconstituted stock is best divided into single-use aliquots; about 28 days at 2-8 °C is a conservative convention for a preserved vial, not a validated shelf life.

Can receptor results in cells be extended beyond the model?

No. Receptor-level observations describe the tested system under defined conditions. Species, receptor expression, concentration, vehicle and timing all change the outcome, so conclusions should stay proportional to the measurement.

Responsible research use

Melanotan-II is a powerful but blunt instrument: it activates several receptors at once, so every conclusion about which receptor is responsible has to be earned with antagonists, selective cell lines or genetic controls. The same discipline applies to the material itself. A ring that has not closed, a mass that does not match or a lot that is not tied to its certificate each undermine a dataset before the first assay is run. Pair every test condition with a vehicle control, characterize responses across concentration and time, prepare solutions consistently, and run independent replicates from more than one vial of a documented lot.

For laboratory research use only; not for human consumption. Nothing in this guide describes use in people or animals outside controlled research settings.

References

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-5758.
2. Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J Am Chem Soc. 1989;111(9):3413-3416.
3. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168.